Evofem Biosciences, Inc.
EVFM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 6.3% | 8.2% | 104.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 80.2% | 64.3% | 73.8% | 50.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -35.7% | -88.2% | -487.5% | -2,010.9% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -45.8% | 290.8% | -455.5% | -2,489% |
| EPS Diluted | -0.092 | 0.051 | -164.59 | -2,962.49 |
| % Growth | -280.9% | 100% | 94.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |